Idh1-Mutant Cholangiocarcinoma

The FDA approved ivosidenib tablets for adults with previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma.

The FDA granted priority review to ivosidenib tablets for patients with previously treated IDH1-mutated cholangiocarcinoma, according to the agent’s manufacturer.

Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated advanced cholangiocarcinoma, according to final results of the phase 3 ClarIDHy trial presented at Gastrointestinal Cancers Symposium.